Notably, cis P-tau is an established early mediator and biomarker of early-stage AD, TBI, and stroke, which are confirmed risk factors for dementia [37,38,39,124,125], with a cis P-tau mAb currently in clinical trials [41,126,127]. This evidence concerns the gene MAPT and Alzheimer disease.